-
-
-
-
-
-
-
GSK preview – likely to guide modest FY26 growth betting on vaccines and specialty drugs
-
-
-
-
-
-
-
GlaxoSmithKline (GSK) PT Lowered to $40 at CFRA
-
-
-
-
-
-
-
Goldman Sachs initiates cover on six European pharma stocks
-
-
-
-
-
-
-
The European version of Magnificent 7 is trading at a 30% discount - Goldman
-
-
-
-
-
-
-
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
-
-
-
-
-
-
-
UPDATE: UBS Downgrades GlaxoSmithKline (GSK:LN) (GSK) to Sell
-
-
-
-
-
-
-
Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
-
1,216,204 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

